{
  "docId": "019dd923-5f69-752d-a9b6-2758ff8024b8",
  "docSlug": "IOYPUci1JeH6qtF9hngI",
  "documentTitle": "See the 21-slide pitch deck a biotech startup used to convince investors like Pfizer to bet on fixing damaged organs",
  "authorId": "Pitchdecks",
  "authorName": "Agomab Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 8,
  "pageCount": 21,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a biological pathway diagram to illustrate the mechanism of action and the specific point of intervention (ALK5).",
  "elementsJson": [
    "process_diagram",
    "bullet_list",
    "headline_text"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b6-2758ff8024b8/8",
  "deckHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b6-2758ff8024b8#slide-8",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Agomab circumvents toxicities through organ restriction.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-9d6a-7169-ab36-9420d3031a8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Biological pathway diagram showing TGF-β signaling and ALK5 inhibition",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20f06e11-105c-4dcd-ad14-3f89a7e0db65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.25
      },
      "kind": "list",
      "text": "TGF-β is highly validated in fibrosis and anti-TGFβ therapies show clinical efficacy in Scleroderma. Targeting the intracellular receptor kinase, ALK-5, blocks the full canonical and non-canonical pathway. But systemic ALK5 inhibitors are severely hampered by cardiotoxicity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f40b9b9-a95a-4fc0-a017-ee191389644f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.68,
        "y": 0.25
      },
      "kind": "list",
      "text": "Agomab circumvents toxicities through organ restriction: AGMB-129: GI-restricted, oral small molecule ALK5 inhibitor. AGMB-447: lung-restricted, inhaled small molecule ALK5 inhibitor.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9db7f18-afee-465d-8c37-1d9719df72d7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Meng et al, Nature 2016; Budi et al. 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "488f7567-fe43-446d-87f3-81f5eface790",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.12,
        "y": 0.06
      },
      "kind": "title",
      "text": "Agomab's TGF-β targeting platform",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3710447f-bbb0-412b-ac56-3d2c0cdae732",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "f53a28bc-5928-4778-947d-aa7c1e40084e",
      "evidence": "The slide structures the argument as a problem (Challenge) and a solution (Our solution).",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}